Herschorn S, Nazir J, Ramos B, Hakimi Z. Supplementary data: Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. CUAJ [Internet]. 2017 Apr. 11 [cited 2024 May 2];11(3-4):E129-33. Available from: https://cuaj.ca/index.php/journal/article/view/4617